Navigation Links
Ketamine Eased Depression in Treatment-Resistant Bipolar Disorder
Date:8/2/2010

MONDAY, August 2 (HealthDay News) -- The anesthetic drug ketamine helps ease depression in patients with treatment-resistant bipolar disorder, a new study finds.

Depressive symptoms are a major part of bipolar disorder, which affects about four percent of Americans at some point in their lives. There are several approved treatments for bipolar disorder, but some patients do not respond to these therapies.

Ketamine acts on the brain's glutamatergic system, which plays a role in information processing and memory formation. Recent research suggests that dysfunction in this brain system may contribute to bipolar disorder, noted Dr. Nancy Diazgranados and colleagues at the U.S. National Institute of Health.

Their study included 18 patients with bipolar depression that didn't improve when treated with the medications lithium or valproate. Two-thirds of the patients were on psychiatric disability and nearly all of them were unemployed.

The patients received an intravenous infusion of either ketamine or a placebo on two days two weeks apart. The order of the infusions was randomly assigned.

The patients' depressive symptoms were assessed before each injection and then 40, 80, 120 and 230 minutes, and one, two, three, seven, 10 and 14 days afterward. Within 40 minutes of receiving ketamine, the patients showed significant improvements in depressive symptoms compared to those who received the placebo. The improvements were most noticeable at day two and remained significant through day three.

At some point during the study, 71 percent of patients responded to ketamine and six percent responded to the placebo. No serious side effects were reported during the trial.

The study, published in the August issue of the journal Archives of General Psychiatry, provides evidence that the brain's glutamatergic system may play a role in bipolar disorder and that targeting it may lead to better treatments, the researchers wrote.

They also said that future research should explore how ketamine's rapid effect on depression can be maintained over the long-term.

Although ketamine has been used off-label as an experimental treatment for depression, it has not been approved by the U.S Food and Drug Administration for that use, according to the U.S. National Institutes of Health.

More information

The U.S. National Institute of Mental Health has more about bipolar disorder.

-- Robert Preidt

SOURCES: JAMA/Archives journals, August 2, 2010, news release; Ketamine Hydrochloride, U.S. National Institutes of Health; ketamine hydrochloride product label, Hospira Inc.


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. U of M study finds fast food chains have significantly decreased trans fats in cooking oils
2. Study shows universal surveillance for MRSA significantly decreased HAIs at PCMH
3. Mayo Clinic Proceedings: Sexual abuse survivors have increased of psychiatric disorders
4. Women with gestational diabetes have increased risk of recurrence in subsequent pregnancies
5. Clothing4all WOWs Yet Again With Customer Appreciation and Increased Sales
6. DTM Systems Is Pleased To Announce That Aaron Alsop Has Achieved The Project Management Professional Credential With The Project Management Institute
7. Lymphoma patients with cardiovascular disease have increased risk of cardiac hospitalization
8. Resource guide for internists released by ACP
9. Counseling increased mammography use among low-income women with health insurance
10. Minor kidney damage in people with type 1 diabetes leads to increased mortality
11. Pre-emptive pain regimen decreased opioid usage in patients undergoing robotic prostatectomy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Ketamine Eased Depression in Treatment-Resistant Bipolar Disorder
(Date:5/5/2016)... ... May 05, 2016 , ... Vitenas Cosmetic Surgery has been named as ... the American Institute of Architects and the Academy of Architecture for Health. The building, ... Harrell Architects, opened to patients in October of 2014. , The ...
(Date:5/5/2016)... , ... May 05, 2016 , ... TIME for Kids ... – today announced a new partnership to reach nearly 1 million children with important ... an instant and is the leading cause of accidental death in children one to ...
(Date:5/5/2016)... ... May 05, 2016 , ... In order to increase ... patterns, Amerec, a Seattle-based steam bath and sauna manufacturer recently launched amerecConnect™ ... interface of the app, developed for both smartphones and personal computers perfectly emulates ...
(Date:5/5/2016)... ... (PRWEB) May 05, 2016 , ... Talent Tech Labs (TTL) is ... eve of National Nurses Week (May 6-12). Currently, HireNurses is a job ... enrollment into the Talent Tech Lab Virtual Incubation program, they will dramatically expand the ...
(Date:5/5/2016)... ... ... Chronic stress can have a silent, yet dangerous, impact on men’s heart health. ... inflammation, both of which raise the risk of heart attack and even stroke,” says ... Massachusetts General Hospital. Chronic stress also can lead to other issues that indirectly affect ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... Israel , May 4, 2016 ... today that BiondVax,s CEO, Dr. Ron Babecoff , will ... New York City . On Thursday, ... Pioneers 2016, a conference presented by Joseph Gunner ... The BiondVax presentation that Dr. Babecoff will be ...
(Date:5/4/2016)... Yissum Research Development Company of the ... had signed an exclusive world-wide licensing and research agreement ... degradation and immunomodulatory drugs for cancer and immune dysfunction, ... first-in-class therapy for hematologic and solid malignancies. Financial terms ... novel technology was developed by Yinon Ben-Neriah , ...
(Date:5/4/2016)... 4, 2016 Valeritas Holdings, Inc. ... alternative public offering (APO). This was accomplished via a ... Inc. and a private placement of approximately 5 million ... share. Under the terms of the reverse ... Holdings, Inc. will trade on the OTC Markets under ...
Breaking Medicine Technology: